Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Wu Samuel
   2. Issuer Name and Ticker or Trading Symbol
APPLIED GENETIC TECHNOLOGIES CORP [AGTC] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DRIVE, SUITE D		 3. Date of Earliest Transaction (Month/Day/Year)
04/01/2014
(Street)

ALACHUA, FL 32615		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 04/01/2014   C   1,376,461 A (1) 1,376,461 I See footnotes (2)
Common Stock 04/01/2014   P(3)   75,735 A $ 12 (3) 1,452,196 I See footnotes (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A-1A Convertible Preferred Stock (1) 04/01/2014   C     11,478,652   (1)   (4) Common Stock 690,678 $ 0 0 I See footnotes (2)
Series B-1 Convertible Preferred Stock (1) 04/01/2014   C     6,409,436   (1)   (4) Common Stock 183,126 $ 0 0 I See footnotes (2)
Series B-2 Convertible Preferred Stock (1) 04/01/2014   C     11,893,926   (1)   (4) Common Stock 339,826 $ 0 0 I See footnotes (2)
Series B-3 Convertible Preferred Stock (1) 04/01/2014   C     5,699,111   (1)   (4) Common Stock 162,831 $ 0 0 I See footnotes (2)
Series B-1 Warrant $ 0.1297 (5) 04/01/2014   C     416,361 (5)   (6) 05/02/2017 Series B-1 Convertible Preferred Stock 416,361 (5) $ 0 0 I See footnotes (2)
Common Stock Warrant $ 4.54 (5) 04/01/2014   C   11,896 (5)     (6) 05/02/2017 Common Stock 11,896 (5) $ 0 11,896 I See footnotes (2)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Wu Samuel
C/O APPLIED GENETIC TECHNOLOGIES CORP.
11801 RESEARCH DRIVE, SUITE D
ALACHUA, FL 32615		   X   X    

Signatures

 /s/ Hemmie Chang, attorney-in-fact for Samuel Wu   04/01/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Each share of convertible preferred stock converted automatically into common stock upon the closing of the Issuer's initial public offering, and had no expiration date.
(2) Shares are held of record by MedImmune Ventures, Inc. The reporting person is a managing director of MedImmune Ventures, Inc. The reporting person disclaims beneficial ownership of all the shares held by MedImmune Ventures, Inc. and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his proportionate pecuniary interest therein.
(3) Shares purchased in the Issuer's initial public offering at the initial public offering price of $12.00 per share.
(4) Not applicable.
(5) Each share of Series B-1 convertible preferred stock automatically converted into shares of common stock upon the closing of the Issuer's initial public offering on a 1-for-35 basis.
(6) Warrant was fully exercisable upon original issue.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.